Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy

Published: 19 January 2022
Man asleep
Patients with narcolepsy find it difficult to remain awake during daytime hours

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy informed by a report produced by SHTAC.

NICE’s guidance recommends:

1. Solriamfetol is recommended as an option for treating excessive daytime sleepiness in adults with narcolepsy with or without cataplexy. This is only if modafinil and either dexamfetamine or methylphenidate have not worked well enough or are not suitable.

1.1 This recommendation is not intended to affect treatment with solriamfetol that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research on sleep conditions  please visit our Research page.

 

Privacy Settings